Related Experiment Video

Updated: Nov 21, 2025

Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.0K

Coronary revascularisation in patients with ischaemic cardiomyopathy

Matthew Ryan1,2, Holly Morgan1,2, Mark C Petrie3,4

  • 1Cardiovascular Division, King's College London, London, UK.

Heart (British Cardiac Society)
|January 13, 2021
PubMed

Insights

Revascularisation may improve outcomes for heart failure patients with ischaemic cardiomyopathy, but more research is needed. Trials are exploring surgical and percutaneous coronary intervention benefits in this population.

Area of Science:

  • Cardiology
  • Cardiovascular Surgery
  • Interventional Cardiology

Background:

  • Heart failure from ischaemic heart disease carries a poor prognosis despite medical management.
  • Patients with ischaemic cardiomyopathy have been underrepresented in revascularisation trials.
  • Revascularisation offers potential benefits like reversing myocardial hibernation and preventing infarction.

Purpose of the Study:

  • To review the current evidence for revascularisation in ischaemic cardiomyopathy.
  • To highlight the need for further randomised controlled trials (RCTs) in this patient group.
  • To outline future research directions in revascularisation for heart failure.

Main Methods:

  • Review of existing literature and clinical trial data, including the STICH trial.
  • Discussion of the lack of RCT evidence for percutaneous coronary intervention (PCI) in ischaemic cardiomyopathy.
  • Anticipation of results from the REVIVED-BCIS2 trial, which addresses the PCI evidence gap.

Main Results:

  • Coronary artery bypass grafting (CABG) showed mortality reduction in the STICH trial, but with early adverse events.
  • No RCT evidence currently exists for PCI in ischaemic cardiomyopathy.
  • The REVIVED-BCIS2 trial is expected to provide crucial data on PCI efficacy.

Conclusions:

  • Further high-quality RCTs are essential to establish the role of revascularisation in ischaemic cardiomyopathy.
  • Future research should focus on patients hospitalised with heart failure, viability testing, mechanistic understanding, and risk prediction models.

Keywords:
chronic coronary diseasecoronary artery disease surgeryheart failure with reduced ejection fractionpercutaneous coronary intervention

More Related Videos

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats06:32

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats

Published on: June 28, 2019

8.3K
Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

9.7K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
125
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
96
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
124
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
200
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
152
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
72